Evgen Pharma PLC (EVG.XLON) Financials
All currency values in £ millions unless otherwise noted
| Income Statement | MAR 2024 | MAR 2023 | MAR 2022 | MAR 2021 |
|---|---|---|---|---|
| Revenues | ||||
| Revenue | £0 | £0 | £0 | £0 |
| Operating Income | -£4 | -£5 | -£3 | -£3 |
| Income Tax Expense | -£0 | -£1 | -£0 | -£1 |
| Net Income | ||||
| Net Income | -£3 | -£4 | -£3 | -£3 |
| Per Share Data | ||||
| Revenue Per Share | £0.00 | £0.00 | £0.00 | £0.00 |
| EPS (Basic) | -£0.01 | -£0.01 | -£0.01 | -£0.02 |
| EPS (Diluted) | -£0.01 | -£0.01 | -£0.01 | -£0.02 |
| Shares Outstanding | 274.9M | 274.9M | 274.9M | 149.2M |
Evgen Pharma (EVG.XLON) financials: revenue, profit and margins
Evgen Pharma (EVG.XLON) generated about £396,000.00 in revenue and -£3 million in net income (a -792.2% net margin) over the trailing twelve months, growing at roughly 42.9% a year. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is Evgen Pharma's (EVG.XLON) revenue?+
Evgen Pharma generated about £396,000.00 in revenue over the trailing twelve months. Revenue has grown at roughly 42.9% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Evgen Pharma profitable?+
Evgen Pharma reported about -£3 million in net loss over the trailing twelve months, a net margin of roughly -792.2%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Evgen Pharma's profit margins?+
Evgen Pharma runs an operating margin of about -899.0%, a net margin of about -792.2%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Evgen Pharma growing?+
Evgen Pharma's revenue has compounded at roughly 42.9% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside EVG.XLON's margins and free cash flow. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.